Lyell Immunopharma Inc (LYEL) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Lyell Immunopharma Inc   (NASDAQ: LYEL)


Lyell Immunopharma Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Lyell Immunopharma Inc's ROI in the second quarter of 2026?
Lyell Immunopharma Inc recorded a cumulative net loss of $-248 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -79.41%.

Within the Healthcare sector 358 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3741 to 3889.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -28.87 % -34.68 % -39.17 % -40.06 % -36.25 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 271 314 291 376 349
Return On Investment (TTM) -79.41 % -74.17 % -78.2 % -84.03 % -75.32 %
LYEL's Overall Ranking # 3889 # 3741 # 2976 # 3605 # 2908
Seq. Investment Change TTM -5.81 % -5.33 % -9.45 % -11.91 % -13.5 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -248 -246 -274 -326 -331

LYEL Company Profile >> Back to LYEL Roi Comparisons >> See Annual LYEL Return On Investment



Return On Investment LYEL's Ranking
Within: No.
Industry # 148
Sector # 359
Overall # 3889

Return On Investment Statistics
High Average Low
-3.97 %
-40.19 %
-84.03 %
(Jun 30 2022)   (Sep 30 2025)



  News about Lyell Immunopharma Inc Return on Investment ROI

Unveiling a New Era in Blood Cancer Treatment Insights on Lyell Immunopharma’s Dual-Targeting CAR T-cell Therapy,

November 5, 2024

Advanced CAR T-cell Therapy Takes Center Stage: Lyell Immunopharma s Promising Clinical Data in Treating B-cell Lymphoma In the rapidly evolving field of immunotherapy, Lyell Immunopharma is making significant strides with its groundbreaking work in CAR T-cell therapies. As a leader in the development of innovative treatments for both solid tumors and hematologic malignancies, Lyell announced a major milestone with the release of initial clinical data from its Phase 1-2 trial of IMPT-314, a variegated treatment designed to combat large B-cell lymphoma. This announcement, forthcoming at the 66th American Society of Hematology (ASH) Annual Meeting, is set to capture the attention of oncologists and hematologists worldwide. Pioneering Novel Approaches in Immunotherapy South San Francisco-based Lyell Immunopharma, which trades on Nasdaq as LYEL, is at the forefront of transforming cancer treatment through next-generation chimeric antigen receptor (CAR) T-cell therapies. These therapies genetically engineer patients own immune cells to target and eradicate cancer cells. The company’s latest candidate, IMPT-314, is specially designed to target both CD19 and CD20 antigens, offering a potent weapon against aggressive B-cell non-Hodgkin s lymphoma.





Financial Statements
Lyell Immunopharma Inc's II. Quarter Investments $ 271 Millions LYEL's Balance sheet
Lyell Immunopharma Inc's II. Quarter Income $ -45 Millions Quarterly LYEL's Income Statement
LYEL's Income by Division See LYEL's Income by Division


LYEL Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 291 437 716 901 1,081
Y / Y Investment Growth -33.5 % -38.91 % -20.55 % -16.67 % -
Net Income in Millions -274 -343 -235 -183 -250
Y / Y Net Income Growth - - - - -
Annual Return On Investment -94.43 % -78.48 % -32.79 % -20.33 % -23.15 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
LYEL's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for LYEL's Competitors
Subscribers only: Roi for Lyell Immunopharma Inc's Suppliers
Subscribers only: Return On Investment for LYEL's Customers

Other Ratios
LYEL's Roa LYEL's Inventory Turnover Ratio LYEL's Growth Rates LYEL's Dividend Statistics
LYEL's Profitability Ratios LYEL's Asset Turnover Ratio LYEL's Dividend Growth
LYEL's Roe LYEL's Valuation Ratios LYEL's Financial Strength Ratios LYEL's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-08T20:47:26+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.